Literature DB >> 9466574

In vivo evidence of apoptosis in arrhythmogenic right ventricular cardiomyopathy.

M Valente1, F Calabrese, G Thiene, A Angelini, C Basso, A Nava, L Rossi.   

Abstract

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a primary heart muscle disease characterized by progressive atrophy of the right ventricular myocardium with fibro-fatty replacement and the risk of electrical instability and sudden death. The disease is often familial and the aetiopathogenesis is still unknown. Recently apoptosis (genetically determined cell death) was postulated to account for progressive loss of myocardium. To establish whether apoptosis is present in ARVC, right ventricular endomyocardial biopsies from 20 patients with clinical and histological diagnosis of ARVC were examined by electron microscopy and terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling method (TUNEL). Apoptotic index was calculated as the percentage of positive nuclei in sections stained by TUNEL. Cell proliferation activity was also assessed by argyrophilic staining of the nucleolar organizer region (AgNOR) and MIB-1 antibody analysis. Twenty biopsies taken from patients during monitoring of cardiac transplantation (grade 0 rejection) served as control. Occurrence of apoptosis was correlated with clinical history duration and the presence of acute symptoms and signs like angina, pyrexia, erythrocyte sedimentation rate and creatine phosphokinase elevation, as well as ST segment elevation on basal electrocardiogram. Electron microscopy and TUNEL revealed presence of apoptotic myocytes in seven cases (35%) with a mean apoptotic index of 24.4+/-9.8. The remaining 13 patients and all of the 20 controls were negative both at the electron microscopy and TUNEL. Presence of apoptosis appeared to be significantly related to clinical history duration of less than 6 months (P < 0.001) and presence of acute symptoms and signs (P = 0.007). AgNOR staining and MIB-1 antibody analysis ruled out cell proliferation activity. In conclusion, apoptosis is present in endomyocardial biopsies of patients with ARVC, especially in the early symptomatic phase of disease. Myocardial destruction with replacement by fat may be episodic rather than gradual and continuous.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9466574      PMCID: PMC1857974     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  33 in total

1.  Apoptosis in thyroid tissue from patients with Hashimoto's thyroiditis.

Authors:  T Kotani; Y Aratake; K Hirai; Y Fukazawa; H Sato; S Ohtaki
Journal:  Autoimmunity       Date:  1995       Impact factor: 2.815

2.  The DAD1 protein, whose defect causes apoptotic cell death, maps to human chromosome 14.

Authors:  I G Yulug; C G See; E M Fisher; I G Ylug
Journal:  Genomics       Date:  1995-03-20       Impact factor: 5.736

3.  Complete heart block and fatal right ventricular failure in an infant.

Authors:  T N James; M M Nichols; D W Sapire; P L DiPatre; S M Lopez
Journal:  Circulation       Date:  1996-04-15       Impact factor: 29.690

4.  The effects of formalin fixation on the detection of apoptosis in human brain by in situ end-labelling of DNA.

Authors:  F D Davison; M Groves; F Scaravilli
Journal:  Histochem J       Date:  1995-12

5.  Effect of postmortem interval on in situ end-labeling of DNA oligonucleosomes.

Authors:  C K Petito; B Roberts
Journal:  J Neuropathol Exp Neurol       Date:  1995-11       Impact factor: 3.685

Review 6.  Apoptosis, oncosis, and necrosis. An overview of cell death.

Authors:  G Majno; I Joris
Journal:  Am J Pathol       Date:  1995-01       Impact factor: 4.307

7.  Arrhythmogenic right ventricular cardiomyopathy. Dysplasia, dystrophy, or myocarditis?

Authors:  C Basso; G Thiene; D Corrado; A Angelini; A Nava; M Valente
Journal:  Circulation       Date:  1996-09-01       Impact factor: 29.690

8.  Ultrastructural detection of DNA strand breaks in apoptotic neural cells by in situ end-labelling techniques.

Authors:  A Migheli; A Attanasio; D Schiffer
Journal:  J Pathol       Date:  1995-05       Impact factor: 7.996

9.  The gene for arrhythmogenic right ventricular cardiomyopathy maps to chromosome 14q23-q24.

Authors:  A Rampazzo; A Nava; G A Danieli; G Buja; L Daliento; G Fasoli; R Scognamiglio; D Corrado; G Thiene
Journal:  Hum Mol Genet       Date:  1994-06       Impact factor: 6.150

10.  A new locus for arrhythmogenic right ventricular cardiomyopathy (ARVD2) maps to chromosome 1q42-q43.

Authors:  A Rampazzo; A Nava; P Erne; M Eberhard; E Vian; P Slomp; N Tiso; G Thiene; G A Danieli
Journal:  Hum Mol Genet       Date:  1995-11       Impact factor: 6.150

View more
  34 in total

1.  Electron microscopy of myocardial tissue. A nine year review.

Authors:  H S Mudhar; B E Wagner; S K Suvarna
Journal:  J Clin Pathol       Date:  2001-04       Impact factor: 3.411

2.  The locus of a novel gene responsible for arrhythmogenic right-ventricular dysplasia characterized by early onset and high penetrance maps to chromosome 10p12-p14.

Authors:  D Li; F Ahmad; M J Gardner; D Weilbaecher; R Hill; A Karibe; O Gonzalez; T Tapscott; G P Sharratt; L L Bachinski; R Roberts
Journal:  Am J Hum Genet       Date:  2000-01       Impact factor: 11.025

Review 3.  Arrhythmogenic right ventricular dysplasia/cardiomyopathy.

Authors:  Victor A Ferrari; Craig H Scott; Cristina Basso
Journal:  Curr Cardiol Rep       Date:  2005-01       Impact factor: 2.931

4.  Case 1/2017 - 26-Year-old Male with Rapidly Progressive Heart Failure.

Authors:  Laís Costa Marques; Rogério Silva de Paula; Ivna Lobo Camilo; Vera Demarchi Aiello
Journal:  Arq Bras Cardiol       Date:  2017-02       Impact factor: 2.000

Review 5.  Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C): a review of molecular and clinical literature.

Authors:  Brittney Murray
Journal:  J Genet Couns       Date:  2012-03-17       Impact factor: 2.537

6.  Arrhythmogenic right ventricular cardiomyopathy mutations alter shear response without changes in cell-cell adhesion.

Authors:  Venkatesh Hariharan; Angeliki Asimaki; Jarett E Michaelson; Eva Plovie; Calum A MacRae; Jeffrey E Saffitz; Hayden Huang
Journal:  Cardiovasc Res       Date:  2014-09-24       Impact factor: 10.787

Review 7.  Etiopathogenesis of arrhythmogenic right ventricular cardiomyopathy.

Authors:  Maithili V N Dokuparti; Pranathi Rao Pamuru; Bhavesh Thakkar; Reena R Tanjore; Pratibha Nallari
Journal:  J Hum Genet       Date:  2005-08-12       Impact factor: 3.172

8.  Characterization of the molecular phenotype of two arrhythmogenic right ventricular cardiomyopathy (ARVC)-related plakophilin-2 (PKP2) mutations.

Authors:  Rosy Joshi-Mukherjee; Wanda Coombs; Hassan Musa; Eva Oxford; Steven Taffet; Mario Delmar
Journal:  Heart Rhythm       Date:  2008-09-06       Impact factor: 6.343

Review 9.  Arrhythmogenic Right Ventricular Cardiomyopathy: Risk Stratification and Indications for Defibrillator Therapy.

Authors:  Alessandro Zorzi; Ilaria Rigato; Barbara Bauce; Kalliopi Pilichou; Cristina Basso; Gaetano Thiene; Sabino Iliceto; Domenico Corrado
Journal:  Curr Cardiol Rep       Date:  2016-06       Impact factor: 2.931

10.  Myocyte necrosis underlies progressive myocardial dystrophy in mouse dsg2-related arrhythmogenic right ventricular cardiomyopathy.

Authors:  Kalliopi Pilichou; Carol Ann Remme; Cristina Basso; Maria E Campian; Stefania Rizzo; Phil Barnett; Brendon P Scicluna; Barbara Bauce; Maurice J B van den Hoff; Jacques M T de Bakker; Hanno L Tan; Marialuisa Valente; Andrea Nava; Arthur A M Wilde; Antoon F M Moorman; Gaetano Thiene; Connie R Bezzina
Journal:  J Exp Med       Date:  2009-07-27       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.